With the Uroplasty Inc. and Vision-Sciences, Inc. merger in the rear view mirror, Cogentix Medical Inc (NASDAQ: CGNT) CEO Rob Kill’s vision of a $100 million company is half way there. The combined revenue from the merger is roughly $50 million, doubling Uroplasty Inc.’s 2014 income.
Cogentix Medical is a global medical device company that designs and manufactures products for the urology, gynecology, ear, nose and throat (ENT) and the gastrointestinal (GI) markets. Product information can be found at the CGNT website.
The completed merger has caught the attention of some analysts who have initiated coverage with a combined mean target of $2.95 a share.
CGNT stock is currently trading at about $1.70 per share just above a 52-week low of $1.42 in late April 2015 and well below a high of $6.20 per share (July 2014) before the merger completion. The next earnings report is due out in early August 2015.
Stay tuned TKO’ers!